| 產(chǎn)品編號 | bs-0174R |
| 英文名稱 | Rabbit Anti-Estrogen Receptor alpha + beta antibody |
| 中文名稱 | 雌激素受體α/β抗體 |
| 別 名 | Estrogen Receptor alpha/beta; Atherosclerosis, susceptibility to, included; DKFZp686N23123; ER Alpha; ER; ER Beta; ER-alpha; ER-beta; ER[a]; ER[b]; Era; ERalpha; Erb; Erb2; ERbeta; ESR; ESR BETA; ESR1; ESR1_HUMAN; ESR2; ESRA; ESRB; Estr; Estra; Estradiol Receptor alpha; Estradiol receptor; Estradiol Receptor beta; ESTRB; Estrogen receptor 1 (alpha); Estrogen Receptor 1; Estrogen receptor 2 (ER beta); Estrogen Receptor 2; Estrogen receptor 2 ER beta; Estrogen receptor alpha; Estrogen receptor; Estrogen receptor beta 4; Estrogen resistance, included; HDL cholesterol, augmented response of, to hormone replacement, included; Myocardial infarction, susceptibility to, included; NR3A1; NR3A2; Nuclear receptor subfamily 3 group A member 1; Nuclear receptor subfamily 3 group A member 2; OTTHUMP00000017718; OTTHUMP00000017719; RNESTROR. Estrogen Receptor α/β; Estrogen Receptor α + β; Estrogen Receptor β; |
 |
Specific References (5) | bs-0174R has been referenced in 5 publications.
[IF=5.81] Wei W. et al. Apigenin, a Single Active Component of Herbal Extract, Alleviates Xerostomia via ERα-Mediated Upregulation of AQP5 Activation.. Front Pharmacol. 2022 Feb;13:818116-818116 IF ; Human.
[IF=5.256] Jia M et al. A platform for primary tumor origin identification of circulating tumor cells via antibody cocktail-based in vivo capture and specific aptamer-based multicolor fluorescence imaging strategy. Analytica Chimica Acta.2019 July. Other ; Human.
[IF=5.131] Yu Tang. et al. hUMSCs Restore Uterine Function by Inhibiting Endometrial Fibrosis via Regulation of the MMP-9/TIMP-1 Ratio in CDDP-Induced Injury Rats. STEM CELLS INT. 2023;2023:8014052 IHC ; Rat.
[IF=4.147] Francesca Salamanna. et al. Development and characterization of a novel human 3D model of bone metastasis from breast carcinoma in vitro cultured. Bone. 2021 Feb;143:115773 IHC ; Human.
[IF=2.97] Li, Fei, et al. "Antiosteoporotic activity of echinacoside in ovariectomized rats." Phytomedicine (2013). IHC-P ; Rat.
|
| 研究領(lǐng)域 | 腫瘤 染色質(zhì)和核信號 信號轉(zhuǎn)導(dǎo) 內(nèi)分泌病 腫瘤細(xì)胞生物標(biāo)志物 表觀遺傳學(xué) |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Rat (predicted: Mouse,Pig) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=1ug/Test,ICC/IF=1:100,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 66kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Estradiol Receptor alpha + beta: 201-300/595 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The estrogen receptor (ER) is a 66 kDa protein that mediates the actions of estrogens in estrogen responsive tissues. It is a member of a large superfamily of nuclear hormone receptors that function as ligand activated transcription factors. The ER gene consists of more than 140 kb of genomic DNA divided into 8 exons. These translate into a protein with six functionally discrete domains, labeled A through F. A second form of the estrogen receptor, ER beta has recently been described. The ER is an important regulator of growth and differentiation in the mammary gland. Presence of ER in breast tumors indicates an increased likelihood of response to anti estrogen (e.g. tamoxifen) therapy. Function: Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1. Subunit: Binds DNA as a homodimer. Can form a heterodimer with ESR2. Isoform 3 can probably homodimerize or heterodimerize with isoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1C and NCOA3 coactivator (By similarity). Interacts with EP300; the interaction is estrogen-dependent and enhanced by CITED1. Interacts with CITED1; the interaction is estrogen-dependent. Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7; the interaction is a ligand-inducible. Interacts with PHB2, PELP1 and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interacts with KDM5A. Interacts with SMARD1. Interacts with HEXIM1. Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7 beta-estradiol (E2) and enhances ERS1-mediated transcription. Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform 4 of TXNRD1. Interacts with MLL2. Interacts with ATAD2 and this interaction is enhanced by estradiol. Interacts with KIF18A and LDB1. Interacts with RLIM (via C-terminus). Interacts with MACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4A blocks binding to PLCG and inhibits estrogen-induced cell proliferation. Interacts with DYNLL1. Interacts with CCDC62 in the presence of estradiol/E2; this interaction seems to enhance the transcription of target genes. Interacts with NR2C1; the interaction prevents homodimerization of ESR1 and suppresses its transcriptional activity and cell growth. Interacts with DYX1C1. Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC and PTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only in the presence of SAV1 and vice-versa. Binds to CSNK1D. Interacts with NCOA2; NCOA2 can interact with ESE1 AF-1 and AF-2 domains simultaneously and mediate their transcriptional synergy. Interacts with DDX5. Interacts with NCOA1; the interaction seems to require a self-association of N-terminal and C-terminal regions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3. Interacts with NRIP1 (By similarity). Subcellular Location: Isoform 1: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=A minor fraction is associated with the inner membrane. Isoform 3: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell membrane; Single-pass type I membrane protein. Note=Associated with the inner membrane via palmitoylation (Probable). At least a subset exists as a transmembrane protein with a N-terminal extracellular domain. Nucleus. Golgi apparatus. Cell membrane. Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where most probably palmitoylation occurs. Associated with the plasma membrane when palmitoylated. Tissue Specificity: Widely expressed. Isoform 3 is not expressed in the pituitary gland. Post-translational modifications: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation probably enhances transcriptional activity. Self-association induces phosphorylation. Glycosylated; contains N-acetylglucosamine, probably O-linked. Ubiquitinated. Deubiquitinated by OTUB1. Dimethylated by PRMT1 at Arg-260. The methylation may favor cytoplasmic localization. Palmitoylated (isoform 3). Not biotinylated (isoform 3). Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation, but not for signaling mediated by the nuclear hormone receptor. Similarity: Belongs to the nuclear hormone receptor family. NR3 subfamily. Contains 1 nuclear receptor DNA-binding domain. SWISS: P03372 Gene ID: 2099 Database links: Entrez Gene: 2099 Human Entrez Gene: 13982 Mouse Omim: 133430 Human SwissProt: P03372 Human 類固醇受體（Steroid Receptors） |
| 產(chǎn)品圖片 |
Protein:
Brain(Rat) lysate at 30ug;
Colon(Rat) lysates, 30ug;
Primary: Anti-ER-alpha/beta (bs-0174R) at 1:200
Secondary: HRP conjugated Goat-Anti-Rabbit IgG(bse-0295G) at 1: 3000
Predicted band size : 58kD,66kD
Observed band size : 58kD
ER-alpha: 66kD; ER-beta: 58kD;
Paraformaldehyde-fixed, paraffin embedded (rat uterus); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Estrogen Receptor alpha + beta) Polyclonal Antibody, Unconjugated (bs-0174R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Tissue/cell: human endometrium tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-ER-alpha/beta Polyclonal Antibody, Unconjugated(bs-0174R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: HUVEC cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (Estrogen Receptor alpha + beta
) Polyclonal Antibody, Unconjugated (bs-0174R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody (bs-0295G-FITC) at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Blank control (blue line): MCF7 (blue).
Primary Antibody (green line): Rabbit Anti-Estrogen Receptor alpha + beta antibody (bs-0174R)
Dilution: 5μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody (white blue line): Goat anti-rabbit IgG-FITC
Dilution: 1μg /test.
Protocol
The cells were fixed with 80% ethanol (Overnight at 4℃) and then permeabilized with 90% ice-cold methanol for 30 min on ice. Cells stained with Primary Antibody for 30 min at room temperature. The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
